| tyyppi : |
Laboratorio |
|
| tutkimus Joukkueet : |
|
| Tekijät : |
|
| Otsikko : |
Atezolizumab (Tecentriq®) - Summary of Product Characteristics |
| Numero : |
Roche Products Limited 2021 |
|
| Todisteiden määrä : |
|
| fyysinen vakaus : |
|
| kemiallinen stabiilisuus : |
|
| Muut menetelmät : |
|
| commentairesvaleur : |
|
Luettelo yhdisteistä
 Atezolizumab
|
 |
 |
 |
 |
3.2 >> 16.8 mg/ml |
2-8°C |
 |
| 30 |
 |
|
|
|
|
|
3.2 >> 16.8 mg/ml |
<30°C |
|
| 24 |
 |
|
|
|
 |
|
3.2 >> 16.8 mg/ml |
2-8°C |
|
| 30 |
|
|
|
|
|
|
3.2 >> 16.8 mg/ml |
<30°C |
|
| 24 |
|
|
|
|
 |
|
3.2 >> 16.8 mg/ml |
2-8°C |
|
| 30 |
|
|
|
|
|
|
3.2 >> 16.8 mg/ml |
<30°C |
|
| 24 |
|
|
|
|
 |
|
3.2 >> 16.8 mg/ml |
2-8°C |
|
| 30 |
|
|
|
|
|
|
3.2 >> 16.8 mg/ml |
<30°C |
|
| 24 |
|
|
|
|
|
| |
+
|
|
|
|
